The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

BACKGROUND: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body m...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Pantano, Francesco, Santoni, Matteo, Procopio, Giuseppe, Rizzo, Mimma, Iacovelli, Roberto, Porta, Camillo, Conti, Alessandro, Lugini, Antonio, Milella, Michele, Galli, Luca, Ortega, Cinzia, Guida, Francesco Maria, Silletta, Marianna, Schinzari, Giovanni, Verzoni, Elena, Modica, Daniela, Crucitti, Pierfilippo, Rauco, Annamaria, Felici, Alessandra, Ballatore, Valentina, Cascinu, Stefano, Tonini, Giuseppe, Carteni, Giacomo, Russo, Antonio, Santini, Daniele
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2015
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4401714/
https://ncbi.nlm.nih.gov/pubmed/25885920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0120427
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker